In Pediatrics, the potential of antagomirs lies in their ability to target and modify the expression of genes involved in pediatric diseases. Conditions such as congenital heart defects, neurodevelopmental disorders, and pediatric cancers often involve dysregulated miRNA expression. By targeting these miRNAs, antagomirs offer a novel therapeutic strategy to address these conditions at the molecular level.
